Savient Announces Completion Of Patient Enrollment In Phase 3 Trials Of Puricase® For Treatment-Failure Gout
Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) announced today that it has reached its Phase 3 enrollment target of 200 patients total, in the two replicate placebo-controlled six-month clinical trials. The trials assess the safety and efficacy of Puricase in patients with treatment-failure gout, under the auspices of a Special Protocol Assessment from the U.S. Food and Drug Administration.
